Compass Pathways PLC banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
United Kingdom UK
Employees
156
IPO date
Sep 18, 2020

Compass Pathways is a biotechnology company focused on developing psilocybin-based treatments for mental health conditions, especially difficult-to-treat depression. It is trying to turn a psychedelic compound into a controlled prescription medicine that can be used in a medical setting with therapist support.

The company does not sell a broad range of consumer products. Its main work is research and clinical development, along with the testing, manufacturing, and regulatory work needed to bring a new drug to market. Its customers, if approved, would be doctors, clinics, hospitals, and patients through the healthcare system, with revenue expected to come from drug sales and related intellectual property once a treatment is commercialized.

What makes Compass different is that it is not a traditional drug maker with many marketed medicines. It is a focused development-stage company trying to build a new treatment category around psychedelic medicine, where the value depends on clinical trial results, regulatory approval, and the ability to deliver therapy in a tightly controlled way.

Compass Pathways PLC Investor Relations

Address
3Rd Floor, 1 Ashley Road
Altrincham, Cheshire
United Kingdom

Business Segments

Psilocybin therapy development

Compass Pathways develops COMP360, a synthetic psilocybin medicine, and runs clinical research to test it for mental health conditions, especially treatment-resistant depression. It also builds the treatment model around...

Customers and revenue model

Management

Mr. Kabir Kumar Nath M.A., M.B.A.

CEO & Director

Biography unavailable

Mr. Matthew Allen Owens

General Counsel & Chief Legal Officer

Biography unavailable

Dr. Guy Goodwin

Chief Medical Officer

Biography unavailable

Ms. Teri Loxam M.B.A.

CFO, Principal Financial Officer & Principal Accounting Officer

Biography unavailable

Dr. Greg Ryslik Ph.D.

Chief Technology Officer

Biography unavailable

Mr. Stephen D. Schultz

Senior Vice President of Investor Relations

Biography unavailable

Mr. Christopher Williams

Chief Communications Officer

Biography unavailable

Ms. Anne Benedict

Chief People Officer

Biography unavailable

Mr. Lars Christian Wilde

Senior Advisor

Biography unavailable

Dr. Susan C. Stansfield Ph.D.

Advisor

Biography unavailable

1 / 10